The Discovery of Ferroptosis (2012)

The story of ferroptosis begins with a mystery about how certain compounds kill cancer cells. In 2003, researchers in Brent Stockwell’s laboratory at Columbia University discovered a small molecule called erastin that could selectively kill cancer cells with mutations in the RAS gene—one of the most common cancer-causing mutations. Strangely, erastin didn’t trigger apoptosis, the usual path to cell death in cancer treatment.

For nearly a decade, scientists investigated this unusual form of cell death. They found another compound, RSL3, that killed cells in a similar non-apoptotic way. Both compounds caused cells to accumulate iron and lipid peroxides before dying, and iron chelators could prevent this death. The cells’ mitochondria shrank and became denser—a morphology unlike any known form of cell death.

In 2012, Scott Dixon and Brent Stockwell published their landmark paper in Cell, formally naming this iron-dependent form of regulated cell death “ferroptosis” (from Latin ferrum for iron, and Greek ptosis for falling).

Connecting Ferroptosis to GPX4 (2014)

The next major breakthrough came when multiple research groups independently discovered that GPX4 (glutathione peroxidase 4) was the critical guardian against ferroptosis.

In 2014, several key papers revealed:

• José Pedro Friedmann Angeli, Marcus Conrad, and colleagues showed that direct GPX4 inhibition triggers ferroptosis
• Wei Gu, Xuejun Jiang, and teams demonstrated that RSL3 kills cells by directly inhibiting GPX4
• These studies established GPX4 as the central regulator preventing lipid peroxide accumulation

This discovery provided the missing mechanistic link: erastin depletes glutathione (GPX4’s essential cofactor) by blocking cysteine import, while RSL3 directly inhibits GPX4 itself. Both paths converge on GPX4 failure, leading to ferroptosis.

The Lipid Connection (2016-2017)

Understanding which lipids matter in ferroptosis came next. In 2016-2017, several groups made crucial discoveries:

• Valerian Kagan, Hülya Bayır, and colleagues at the University of Pittsburgh identified that specific oxidized phospholipids—particularly those containing polyunsaturated fatty acids like arachidonic acid and adrenic acid—are the actual executioners in ferroptosis

• Joseph Witztum, Kimberly Pratt, and teams showed that ACSL4 (an enzyme that incorporates these fatty acids into membranes) determines cellular sensitivity to ferroptosis. Cells lacking ACSL4 are highly resistant to ferroptosis

These discoveries revealed that ferroptosis susceptibility isn’t just about antioxidant defenses—it’s also about lipid composition. Cells with more polyunsaturated membrane lipids are more vulnerable.

Beyond GPX4: Alternative Defense Pathways (2019)

A paradigm shift occurred in 2019 when researchers discovered that GPX4 isn’t the only way cells prevent ferroptosis:

• Eikan Mishima, Takaaki Akaike, and colleagues in Japan discovered FSP1 (ferroptosis suppressor protein 1), which reduces coenzyme Q10 to create a parallel antioxidant defense system

• Jen-Tsan Chi and Stuart Schreiber‘s groups independently confirmed FSP1’s role, showing it operates completely independently of GPX4

Shortly after, Guang Lei‘s group discovered the GCH1-BH4 pathway as yet another GPX4-independent defense mechanism, where tetrahydrobiopterin (BH4) acts as a lipid antioxidant.

These discoveries revealed that cells have multiple, redundant systems to prevent ferroptosis—much more sophisticated than initially thought.

Ferroptosis in Disease (2015-Present)

As the molecular mechanisms became clearer, researchers began connecting ferroptosis to human diseases:

Neurodegeneration (2015-2017)

• Studies linked ferroptosis to Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease
• Brain tissue from patients showed markers of iron accumulation and lipid peroxidation
• Ferroptosis inhibitors showed protective effects in animal models of neurodegeneration

Ischemia-Reperfusion Injury (2014-2018)

• Multiple groups demonstrated ferroptosis occurs during heart attack, stroke, and organ transplantation
• Ferroptosis inhibitors reduced tissue damage in animal models
• Iron chelation and lipid antioxidants showed therapeutic promise

Cancer Therapy (2013-Present)

• Certain cancers, particularly those with high iron content or specific metabolic profiles, proved vulnerable to ferroptosis induction
• Some therapy-resistant cancers remained susceptible to ferroptosis
• Clinical trials began testing ferroptosis-inducing strategies

Kidney Disease (2016-Present)

• Ferroptosis was identified in acute kidney injury and chronic kidney disease
• Tubular epithelial cells proved particularly vulnerable to ferroptotic death

Recent Advances and Emerging Concepts (2020-Present)

The field continues to expand rapidly:

• Immunology connections: Discovery that certain immune cells can induce ferroptosis in target cells, and that ferroptosis affects immune responses

• Metabolic regulation: Understanding how cellular metabolism (glucose, amino acids, lipids) influences ferroptosis sensitivity

• Subcellular location: Recognition that different cellular compartments (mitochondria, endoplasmic reticulum, lysosomes) contribute to ferroptosis regulation

• In vivo relevance: Growing evidence from animal models and human studies confirming ferroptosis occurs in living organisms, not just cell culture

• Therapeutic development: First-generation ferroptosis inhibitors and inducers moving toward clinical applications

The Impact and Future

In just over a decade, ferroptosis has evolved from an unexplained observation to a major field of biomedical research. What started with two mysterious compounds that killed cancer cells has revealed:

• A fundamental new way that cells die
• Deep connections between iron metabolism, lipid chemistry, and cell fate
• Therapeutic opportunities across numerous diseases
• A more complex and nuanced understanding of how cells balance survival and death

The rapid pace of discovery continues. Each year brings new regulatory mechanisms, disease connections, and therapeutic possibilities. Ferroptosis research has attracted scientists from diverse fields—cancer biology, neuroscience, metabolism, immunology, and more—all contributing pieces to an increasingly complete picture.

The history of ferroptosis demonstrates how basic scientific curiosity—investigating how a compound kills cells—can unlock profound insights with far-reaching medical implications.